Ipamorelin was introduced as the first selective growth hormone secretagogue because it triggered a GH pulse without raising cortisol or prolactin. That selectivity was measured in swine and rats, not in people, and an FDA advisory committee later voted 0 to 12 against allowing it in compounding.
Ipamorelin is generally well tolerated at the doses used in studies, and its side-effect reputation is milder than the older peptides it replaced. The harder facts are not pharmacologic but regulatory. The FDA flags ipamorelin as a compounding safety risk, an advisory committee voted against it, and it is banned in sport at all times. Anyone weighing it should hold the mild day-to-day profile and the regulatory picture in view together.
- Ipamorelin was the first selective secretagogue: it raised GH without raising cortisol or prolactin in animal models [1]
- That selectivity is from swine and rats, so the cortisol advantage is strongly suggested by animal data rather than proven in people [1]
- Its only published human trial reported tolerability close to placebo, but tested postoperative ileus and missed its endpoint [2]
- Fluid retention and reduced glucose tolerance are the class cautions that come with raising GH and IGF-1 [6]
- FDA lists ipamorelin among bulk substances flagged as a compounding safety risk, citing immunogenicity and serious adverse events including death with intravenous use [3]
- An FDA advisory committee voted 0 in favor and 12 against permitting it in compounding, and it is prohibited in sport at all times [4][5]
The Day-to-Day Side-Effect Profile
At study doses, the common effects are the mild ones shared by most GH-axis peptides. Local injection-site reactions, transient headache, lightheadedness, and short-lived flushing are what get reported. Because ipamorelin also works through the ghrelin receptor, a brief increase in hunger after dosing is a mechanistic effect worth expecting rather than a surprise.
- Injection-site redness, itching, or a small welt that settles within a day
- Transient headache or lightheadedness shortly after dosing
- A short-lived flush or feeling of warmth
- A brief rise in appetite, since ipamorelin binds the same receptor as the hunger hormone ghrelin
The human tolerability data are thin but real. Ipamorelin's only published efficacy trial tested it for postoperative ileus and missed its primary endpoint, with adverse events in the range of placebo [2]. That trial was short and in surgical patients, so it says little about months of subcutaneous use for body composition, which has never been tested in a published human trial.
The Selectivity Claim, Read Honestly
The reason ipamorelin displaced GHRP-6 and GHRP-2 is selectivity. In the foundational work it was introduced as the first selective growth hormone secretagogue [1], releasing GH without raising ACTH or cortisol even at doses more than 200 times its GH ED50, while the older peptides raised both. That is a genuine advantage, because a cortisol rise works against the sleep and recovery most people start therapy for.
The study was done in swine and rats, so the cortisol selectivity rests on animal data rather than human measurement. The prolactin point is weaker still: none of the secretagogues tested affected prolactin, which makes it a property of the class in that experiment rather than an ipamorelin-specific edge [1].
The Effects of Raising GH and IGF-1
Any peptide that raises GH and IGF-1 carries the same downstream cautions, and ipamorelin is no exception. The nearest FDA-approved GH-axis drug documents peripheral edema, joint aches, and reduced glucose tolerance as class effects [6]. Mild fluid retention is the version most people notice, and it tends to ease at a lower dose.
Anyone with prediabetes or diabetes should have glucose monitored, since raising GH lowers insulin sensitivity. As with any GH-axis therapy, active malignancy is a reason not to use it, because IGF-1 promotes cell growth and no long-term data address that risk for ipamorelin.
The Regulatory Signals, Rarely Disclosed at Sale
This is the part of the safety picture most likely to be left off a product page. FDA states there are no approved products containing ipamorelin in any form and lists ipamorelin acetate among bulk drug substances flagged for safety risks in compounding [3]. The stated concerns are immunogenicity risk from aggregation or impurities, unnatural amino acids that complicate characterization, and published serious adverse events including death when it was given intravenously for gastric motility.
In October 2024, the FDA Pharmacy Compounding Advisory Committee voted on whether to add ipamorelin to the 503A bulks list. The result was 0 in favor, 12 against, 1 abstention for both the free base and acetate forms, with the committee citing a lack of data supporting safety and efficacy [4]. Ipamorelin is also named on the 2026 WADA Prohibited List under section S2.2.4, prohibited at all times in and out of competition [5].
Using It More Carefully
Ipamorelin is rarely run alone, so its side-effect management usually rides alongside a GHRH analog like sermorelin or CJC-1295. The discipline is the same either way. A baseline IGF-1 before starting, a 90-day retest, and a dose reduction when a result lands above the age-adjusted range keep the manageable effects in check.
The pharmacy is the other variable. Compounded peptides are not verified by the FDA for quality before sale, and the immunogenicity concern in the FDA flag is a manufacturing problem, so ask which pharmacy fills the prescription and whether a Certificate of Analysis is available for the lot. A program that skips the baseline lab has removed the one measurement that tells you whether the dose is doing what it should.
Ipamorelin is almost always stacked with a GHRH analog, and the side effects that matter track with IGF-1. SystemLabs tests IGF-1 before prescribing and formulates ipamorelin and CJC-1295 on clinical indication, so the peptide is added on evidence and measured at 90 days rather than dosed by default.
Frequently Asked Questions
What are the side effects of ipamorelin?
At study doses the common effects are mild: injection-site reactions, transient headache or lightheadedness, brief flushing, and a short rise in appetite from its action on the ghrelin receptor. The effects of raising GH and IGF-1, such as fluid retention and reduced glucose tolerance, apply as class cautions [6], and its only published human trial reported tolerability close to placebo [2].
Does ipamorelin raise cortisol?
The selectivity data says it does not, but that data is from swine and rats rather than people. In the foundational study, ipamorelin did not raise ACTH or cortisol above GHRH-stimulation levels even at more than 200 times its GH dose, while GHRP-6 and GHRP-2 did [1]. Treat the cortisol advantage as strongly suggested by animal data, not proven in humans.
Is ipamorelin safe?
Its day-to-day profile is mild, but the regulatory picture is the honest counterweight. FDA lists ipamorelin among bulk substances flagged as a compounding safety risk, citing immunogenicity and serious adverse events including death with intravenous use, and an advisory committee voted 0 to 12 against it for compounding [3][4]. It is not an FDA-approved drug, and there is no published long-term human safety study.
Does ipamorelin cause water retention?
It can, as a downstream effect of raising GH and IGF-1 rather than a direct action of the peptide. Mild fluid retention that shows as puffy hands or ankles matches the peripheral edema documented for the approved GH-axis drug and usually eases at a lower dose [6].
Is ipamorelin banned in sport?
Yes. The 2026 WADA Prohibited List names ipamorelin explicitly under section S2.2.4, prohibited at all times in and out of competition alongside other growth hormone secretagogues [5]. Anyone subject to anti-doping testing should treat it as off the table.
References
- Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, 2014. PMID: 25331030. https://pubmed.ncbi.nlm.nih.gov/25331030/
- Certain bulk drug substances for use in compounding that may present significant safety risks FDA.gov, Human Drug Compounding, 2026. Content current as of 04/22/2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Summary minutes of the Pharmacy Compounding Advisory Committee meeting, October 29, 2024 FDA Advisory Committee, 2024. PCAC summary minutes. https://www.fda.gov/media/185412/download
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
- EGRIFTA SV (tesamorelin) for injection: full prescribing information DailyMed, U.S. National Library of Medicine, 2025. FDA-approved labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
